Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

(2022) Yoon-Koo Kang et al.   LANCET ONCOLOGY

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

(2022) Yuichiro Doki et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

(2022) Zi-Xian Wang et al.   CANCER CELL

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

(2022) Sylvie Lorenzen et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

(2022) Kohei Shitara et al.   NATURE

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

(2022) Zhihao Lu et al.   BMJ-British Medical Journal

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy

(2022) Joe Yeong et al.   Gastric Cancer

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

I’m Not Putting on that Floral Gown: Enforcement and Resistance of Gender Expectations for Transgender People with Cancer

(2021) Ash B. Alpert et al.   PATIENT EDUCATION AND COUNSELING

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

(2021) Narikazu Boku et al.   Gastric Cancer

PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy

(2021) Soomin Ahn et al.   MODERN PATHOLOGY

LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study

(2021) J. Xu et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

(2021) Charles S. Fuchs et al.   Gastric Cancer

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

(2021) Huiyan Luo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

(2021) Jong-Mu Sun et al.   LANCET

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

(2021) Yelena Y Janjigian et al.   LANCET

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

(2021) Hyun Cheol Chung et al.   CANCER

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

(2021) Bryan J. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

(2021) Yelena Y. Janjigian et al.   NATURE

Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

(2020) Brianna Lauren et al.   Journal of Oncology

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global burden of oesophageal and gastric cancer by histology and subsite in 2018

(2020) Melina Arnold et al.   GUT

Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology

(2020) Manali I. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

(2020) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

1502TiP Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs - RAMOS, a randomized phase II trial of the German Gastric Group of the AIO

(2020) S. Lorenzen et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

(2020) Markus Moehler et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

(2018) Y -J Bang et al.   ANNALS OF ONCOLOGY

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

(2018) Josep Tabernero et al.   LANCET ONCOLOGY

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Kohei Shitara et al.   LANCET ONCOLOGY

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

(2017) Timothy Gilligan et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology

(2017) Angela N. Bartley et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations

(2017) Jennifer Griggs et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Betty R. Ferrell et al.   JOURNAL OF CLINICAL ONCOLOGY

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

(2016) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

(2013) Kohei Shitara et al.   Gastric Cancer

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

GRADE guidelines: 3. Rating the quality of evidence

(2011) Howard Balshem et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability

(2011) Richard N Shiffman et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

(2011) Sonya Blesser Streeter et al.   Journal of Oncology Practice

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

(2009) Neal J. Meropol et al.   JOURNAL OF CLINICAL ONCOLOGY